RECOVERY Trial

RECOVERY Trial is a clinical trial initiated by the United Kingdom in response to the COVID-19 pandemic. The trial aims to identify treatments that may be beneficial for people hospitalized with suspected or confirmed COVID-19. The RECOVERY (Randomised Evaluation of COVid-19 thERapY) Trial is one of the world's largest randomized trials for coronavirus treatments, testing a range of potential therapies.

Background[edit | edit source]

The RECOVERY Trial was launched in March 2020 as a randomized clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone, Hydroxychloroquine, Lopinavir-Ritonavir, Azithromycin, Convalescent plasma, and Tocilizumab. The trial is coordinated by the University of Oxford.

Methodology[edit | edit source]

The RECOVERY Trial uses a randomized controlled trial design, which is considered the gold standard in clinical research. Patients admitted to the participating hospitals with suspected or confirmed COVID-19 are randomly allocated to receive one of the trial treatments or the standard hospital care.

Findings[edit | edit source]

The RECOVERY Trial has made several significant findings since its inception. The trial found that low-dose dexamethasone, a steroid treatment, reduced deaths by one-third in ventilated patients and by one fifth in other patients receiving oxygen only. However, it found no benefit for patients who did not require respiratory support.

Impact[edit | edit source]

The findings of the RECOVERY Trial have had a significant impact on the treatment of hospitalized COVID-19 patients worldwide. The trial's results have influenced guidelines for the treatment of COVID-19 in the UK and globally.